SCHEMBL6628461

SCHEMBL6628461

CC(C)(C)OC(=O)N1CCCN(c2ccc(C(F)(F)F)cc2N)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
GPR119 Q8TDV5 3/20 0.50
ALDH1A1 P00352 2/20 0.50
LMNA P02545 2/20 0.50
KDM4E B2RXH2 1/20 0.50
SMARCA2 P51531 1/20 0.47
SMARCA4 P51532 1/20 0.47
PBRM1 Q86U86 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MC4R P32245 1/20 0.46
PDK2 Q15119 1/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MGLL Q99685 2/20 0.44
ABHD6 Q9BV23 2/20 0.44
CYP2D6 P10635 1/20 0.44
PLA2G7 Q13093 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30301736 0.95 ALDH1A1 (0.54) MAPTGPR119ALDH1A1LMNAKDM4E
SCHEMBL114538 0.95 ALDH1A1 (0.54) MAPTGPR119ALDH1A1LMNAKDM4E
SCHEMBL17305300 0.88 MAPT (0.60) MAPTGPR119ALDH1A1LMNASMARCA2
SCHEMBL161275 0.84 MEN1 (0.59) MAPTALDH1A1LMNAKDM4ESMARCA2
SCHEMBL14453584 0.83 GPR119 (0.55) MAPTGPR119ALDH1A1LMNASMARCA2
SCHEMBL30301712 0.83 MAPT (0.65) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL6629173 0.83 MAPT (0.65) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3922455 0.82 GPR119 (0.69) MAPTGPR119ALDH1A1LMNAMEN1
SCHEMBL4422111 0.82 GPR119 (0.54) MAPTGPR119ALDH1A1LMNASMARCA2
SCHEMBL31142873 0.82 GPR119 (0.69) MAPTGPR119ALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389194-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-18 EP disclosed
US-20030095958-A1 Inhibitors of bace VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 US disclosed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030095958-A1 Inhibitors of bace BACE2, BACE1, APP MAPT 72/4885GPR119 3178/4885ALDH1A1 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.